Research and Markets: Competitive Analysis of U.S. Pharmaceutical Industry, 2011

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/334c12/competitive_analys) has announced the addition of the "Competitive Analysis of U.S. Pharmaceutical Industry, 2011" report to their offering.

This report is a detailed analysis of leading pharmaceutical companies in the U.S. pharmaceutical industry. Key players analysed in the report are - Pfizer, Merck, AstraZeneca, Novartis and Eli Lilly.

Comparative analysis of companies is done on the basis of their sales and profits and other financial information. Detailed ratio analysis compares these companies on the basis of their revenue growth, profitability, efficiency, financial strength and investment returns.

This report also presents a brief profile and SWOT analysis of these companies along with their financial analysis and ratio analysis vis-a-vis industry. Lastly, this report analyses the M&A activity in the U.S. Pharmaceutical Industry in recent years.

Key Report Takeaways: U.S. healthcare spending in 2010 was US$2.3 trillion or 16% of GDP, more than any other country in the world. United States is the largest pharmaceutical market globally, with 2010 sales of US$307 billion or 40% of global sales.

In 2010, U.S. pharmaceutical sales grew at 2. 3%; and since 2001 market has grown at a CAGR of 6. 6%. Pharmaceutical sales in the United States are expected to reach US$328 billion in 2011 and up to US$420 billion by 2015; growing at a CAGR of 6.4% between 2010 and 2015.

Highly competitive industry with top 5 companies accounting for leading the pack is Pfizer with a market share of 8.52% followed by Merck (6.11%), AstraZeneca (5.95%), Novartis (5.1%) and Eli Lilly (4.65%).

Merck, AstraZeneca and Eli Lilly had the best profit margins among the peer group while Pfizer and Eli Lilly had better financial condition and efficiency ratio. In terms of investment ratios, AstraZeneca and Eli Lilly are better placed than their peers.

In last 2 years, apart from Merck, all other companies ended the period with a positive growth in their share prices with Novartis leading the peer group with 17% increase in its share prices.

Key Topics Covered:

U.S. Healthcare Sector

Industry Overview

Generic Drugs Market Assessment

Distribution and Supply Chain Analysis

Trend Analysis

Growth Drivers and Constraints

Government Policies and Regulations

Competitive Landscape

Mergers & Acquisitions Assessment

For more information on this report visit http://www.researchandmarkets.com/research/334c12/competitive_analys.



CONTACT:

Research and Markets
Laura Wood, Senior Manager
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.